Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
The most effective method to Guarantee Simple Availability in Seniors' SUVs - 2Relentless rise in carbon pollution from fossil fuels slightly dampens climate-fighting hopes
- 3California warns of death cap mushrooms outbreak resulting in 3 deaths
- 4Best Augmented Simulation Ride: Which One Feels Generally Genuine?
- 5Novartis to build manufacturing hub in North Carolina, creating 700 jobs
- Want to make America healthy again? Stop fueling climate change
- My Pioneering Excursion: Building a Startup
- He made a name for himself posting thirst traps on TikTok. Now he's the star of a wildly popular rom-com.
- Most loved VR Game for Wellness: Which Keeps You Dynamic?
- As world leaders enter climate talks, people in poverty have the most at stake
- Everyone knows F1 is for the girls. I wandered into the Las Vegas desert to find out why.
- Interstellar comet 3I/ATLAS isn't an alien spacecraft, astronomers confirm. 'In the end, there were no surprises.'
- Strength training is crucial after menopause. How to make the most of your workouts
- Tech Development Disclosed: A Survey of \Usefulness and Configuration in Concentration\ Tech Item
